CARDURA XL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cardura Xl, and what generic alternatives are available?
Cardura Xl is a drug marketed by Viatris and is included in one NDA.
The generic ingredient in CARDURA XL is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cardura Xl
A generic version of CARDURA XL was approved as doxazosin mesylate by APOTEX on October 18th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CARDURA XL?
- What are the global sales for CARDURA XL?
- What is Average Wholesale Price for CARDURA XL?
Summary for CARDURA XL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 106 |
Clinical Trials: | 11 |
Patent Applications: | 1,730 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CARDURA XL |
DailyMed Link: | CARDURA XL at DailyMed |
![CARDURA XL drug patent expirations Drug patent expirations by year for CARDURA XL](/p/graph/s/t/CARDURA_XL-patent-expirations.png)
![Drug Prices for CARDURA XL](/p/graph/drug-price/CARDURA+XL.png)
See drug prices for CARDURA XL
![Drug Sales Revenue Trends for CARDURA XL](/p/graph/drug-sales-revenues/CARDURA+XL.png)
Recent Clinical Trials for CARDURA XL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Texas Health Science Center, Houston | Phase 1 |
Brown University | Phase 2 |
University of California, Los Angeles | Phase 3 |
Pharmacology for CARDURA XL
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |
US Patents and Regulatory Information for CARDURA XL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viatris | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-001 | Feb 22, 2005 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Viatris | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-002 | Feb 22, 2005 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CARDURA XL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viatris | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-002 | Feb 22, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CARDURA XL
See the table below for patents covering CARDURA XL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 1315687 | FORME GALENIQUE POUR LIBERER UN MEDICAMENT DESTINE AU TRAITEMENT DES HUMAINS (DOSAGE FORM FOR DISPENSING DRUG FOR HUMAN THERAPY) | ⤷ Sign Up |
Hong Kong | 1003980 | ⤷ Sign Up | |
Denmark | 175637 | ⤷ Sign Up | |
Denmark | 135389 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |